Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Labopharm Reviews its Assets for Potential Sale

By Pharmaceutical Processing | April 29, 2011

MONTREAL
— Labopharm Inc. is reviewing its assets for a potential sale or merger as part
of the company’s ongoing restructuring efforts.

The Laval,
Que.-based drug developer said Friday that it believes it has the potential to
sell the rights to its painkiller called Intellitab as well as the time-release
drug technology called polymeric nano-delivery.

The company also plans to look at combining its businesses
to create shareholder value, though it has no assurance that either plan will
result in a transaction.

The decision comes as Labopharm talks to Gruppo Angelini,
its U.S.
partner for the antidepressant Oleptro, with the goal of reworking the terms of
their agreement.

“Although we continue to believe that Oleptro is a
valuable product for the treatment of depression, we feel it is in the
company’s best interest to come to an agreement with Angelini that allows us to
preserve our cash,” said president and CEO Mark D’Souza in a release.

It did not provide any further details on the discussions.

In March, Labopharm announced it was eliminating 38
positions, or nearly 30 per cent of its current workforce with the goal of
saving $3.8 million per year.

Labopharm has been trying to stop its mounting financial
losses. For the 2010 financial year, it lost $28.9 million with $29.4 million
of revenue from all sources. In 2009, it lost $26.1 million with $24.6 million
of revenue.

 

Related Articles Read More >

Astellas
Astellas to spend $70M on new biotech campus in South San Francisco
Rainin
Mettler Toledo Rainin expands facilities in Vacaville, California
Elemental Machines
Elemental Machines aims to enlist lab freezers in fight against climate change 
Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards